Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point …

Oct 3, 2023 · Eli Lilly’s scope in cancer is expanding to radiopharmaceuticals with the $1.4 billion acquisition of Point Biopharma Global, a company in late-stage clinical development with two …

CouponFollow Extension

$1
OFF

Eli Lilly Jumps Into Radiopharmaceuticals Via $1.4B Point …

4 weeks from now

medcitynews.com

$12.50
OFF

Lilly Completes Acquisition Of POINT Biopharma - Yahoo Finance

4 weeks from now

Dec 27, 2023 · Lilly's tender offer to acquire all of the issued and outstanding shares of common stock of POINT at a purchase price of $12.50 per share in cash, without interest and less any …

yahoo.com

$1
OFF

Eli Lilly Forays Into Radiopharmaceuticals With $1.4B POINT Buy

4 weeks from now

Oct 3, 2023 · Eli Lilly will acquire POINT Biopharma as the drugmaker looks to definitively expand its oncology capabilities into next-gen radioligand therapies. Per the agreement, Lilly will …

pharmamanufacturing.com

$1
OFF

Eli Lilly Inks Another Radiopharma Deal, Gaining Option To Buy Startup

4 weeks from now

Jul 1, 2024 · Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1 …

biopharmadive.com

$60
OFF

Lilly Pays Aktis $60M To Further Dial Into Radiopharma Signal

4 weeks from now

May 21, 2024 · Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets. Lilly …

fiercebiotech.com

FAQs about Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point … Coupon?

Will Eli Lilly buy point Biopharma?

Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1.4 billion. Per acquisition terms, Lilly will pay $12.50 per Point share, a premium of about 87% to what the biotechnology company’s stock closed at Monday. ...

Will Eli Lilly buy radionetics oncology?

Scott Olson via Getty Images Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1 billion. Lilly will pay Radionetics $140 million upfront for the option rights under the deal, which the companies announced Monday. ...

Could Lilly & point accelerate the development of radiopharmaceuticals?

Joe McCann, Ph.D., CEO of POINT added: "The combination of POINT's team, infrastructure and capabilities with Lilly's global resources and experience could significantly accelerate the discovery, development and global access to radiopharmaceuticals. ...

Why is Lilly partnering with a pharma company to develop radiopharma?

Recent improvements in manufacturing and supplying the complex treatments have boosted investment in the field, drawing interest from large pharma companies like Lilly as well as new drug startups. The Point deal appears to be part of a broader plan by Lilly to build a presence in radiopharma drug development. ...

Will Eli Lilly buy a treatment for metastatic prostate cancer?

One of the experimental drugs Eli Lilly will acquire is a treatment for metastatic prostate cancer. Dr_Microbe via Getty Images Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1.4 billion. ...

Is Lilly behind the curve in radiopharmaceuticals?

Lilly is slightly behind the curve, striking the deal well after Novartis dove in headfirst to the radiopharmaceuticals space. While Lilly has previously put money behind radiopharmaceutical companies—like supporting Mariana Oncology’s $175 million series B last month—Novartis has made radiopharmaceuticals a pillar of its cancer strategy. ...